The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy
Background. Diabetes mellitus (DM) is one of the socially significant diseases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years — in 25 % of patients with DM. About 80...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaslavsky O.Yu.
2019-08-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | http://iej.zaslavsky.com.ua/article/view/180042 |
| _version_ | 1819109028032151552 |
|---|---|
| author | M.V. Vlasenko A.V. Palamarchuk S.V. Shkarivska |
| author_facet | M.V. Vlasenko A.V. Palamarchuk S.V. Shkarivska |
| author_sort | M.V. Vlasenko |
| collection | DOAJ |
| description | Background. Diabetes mellitus (DM) is one of the socially significant diseases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years — in 25 % of patients with DM. About 80 % of patients with DPN are asymptomatic, and the painful form of DPN is diagnosed in 10–20 % of cases. Sometimes, DPN precedes the onset of clinical signs of DM. For adequate treatment of DPN, it is necessary to know that pathogenesis of neuropathy in DM is associated with overall metabolic lesion of neuronal membranes. The objective was to study the effectiveness of Nucleo C.M.P. Forte in the comprehensive treatment of DPN. Materials and methods. Thirty patients with DM types 1 and 2 (8 men and 22 women) and DPN were examined. The level of glycated hemoglobin was from 7.1 to 10.4 %. The first group (15 patients) received: alpha-lipoic acid at a dose of 600 mg intravenously, B vitamins: injections — for 10 days while in hospital and tablets — for one month at home. The second group (15 patients) before treatment received by group 1 was treated with Nucleo C.M.P. Forte intramuscularly for 10 days while in hospital, then 1 capsule twice a day for 2 months. In all patients before administration of the drug, after 10 days of in-hospital treatment and 2 months after treatment, clinical neurological examination was performed to evaluate neurological status, as well as dynamic examination using special clinical questionnaires (scales): Neurological Symptom Score and Total Symptom Score. Results. Patients in both the first group and the second groups had a statistically positive effect on the symptoms after 10 days of in-patient treatment according to Neurological Symptom Score. The severity of neuropathy in first group before treatment was 10.23 ± 0.35 points, and after treatment — 7.62 ± 0.26 points, p < 0.001; in the second group, before treatment — 10.23 ± 0.35 points, and after treatment — 8.00 ± 0.30 points, p < 0.001. According to Total Symptom Score, the severity of neuropathy symptoms decreased significantly in both group 1 (8.27 ± 0.47 points before treatment and 6.27 ± 0.12 points after treatment, p < 0.001) and group 2 (8.40 ± 0.45 points before treatment and 6.53 ± 0.14 points after treatment, p < 0.001). Further studies showed that after 2 months of treatment in patients in first group, Neurological Symptom Score (10.23 ± 0.35 points, p > 0.05) and Total Symptom Score (7.87 ± 0.38 points, p > 0.05) returned to the baseline or the changes were unreliable. Two-month administration of Nucleo C.M.P. Forte had a statistically positive effect on the symptoms of neuropathy according to Neurological Symptom Score (7.27 ± 0.51 points, p < 0.001) and Total Symptom Score (6.53 ± 0.14 points, p < 0.001). Conclusions. The use of Nucleo C.M.P. Forte in the comprehensive treatment of patients with diabetes mellitus can prevent disorders that occur as a result of diabetic polyneuropathy. Long-term statistically significant positive effect of Nucleo C.M.P. Forte on neuropathy symptoms was revealed. |
| first_indexed | 2024-12-22T03:19:18Z |
| format | Article |
| id | doaj.art-11887583d08f47de89eec254d2d2ce42 |
| institution | Directory Open Access Journal |
| issn | 2224-0721 2307-1427 |
| language | English |
| last_indexed | 2024-12-22T03:19:18Z |
| publishDate | 2019-08-01 |
| publisher | Zaslavsky O.Yu. |
| record_format | Article |
| series | Mìžnarodnij Endokrinologìčnij Žurnal |
| spelling | doaj.art-11887583d08f47de89eec254d2d2ce422022-12-21T18:40:46ZengZaslavsky O.Yu.Mìžnarodnij Endokrinologìčnij Žurnal2224-07212307-14272019-08-0115538639010.22141/2224-0721.15.5.2019.180042180042The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathyM.V. Vlasenko0A.V. Palamarchuk1S.V. Shkarivska2National Pirogov Memorial Medical University, Vinnytsia, UkraineNational Pirogov Memorial Medical University, Vinnytsia, UkraineVinnytsia Regional Clinical Highly-Specialized Endocrinology Center, Vinnytsia, UkraineBackground. Diabetes mellitus (DM) is one of the socially significant diseases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years — in 25 % of patients with DM. About 80 % of patients with DPN are asymptomatic, and the painful form of DPN is diagnosed in 10–20 % of cases. Sometimes, DPN precedes the onset of clinical signs of DM. For adequate treatment of DPN, it is necessary to know that pathogenesis of neuropathy in DM is associated with overall metabolic lesion of neuronal membranes. The objective was to study the effectiveness of Nucleo C.M.P. Forte in the comprehensive treatment of DPN. Materials and methods. Thirty patients with DM types 1 and 2 (8 men and 22 women) and DPN were examined. The level of glycated hemoglobin was from 7.1 to 10.4 %. The first group (15 patients) received: alpha-lipoic acid at a dose of 600 mg intravenously, B vitamins: injections — for 10 days while in hospital and tablets — for one month at home. The second group (15 patients) before treatment received by group 1 was treated with Nucleo C.M.P. Forte intramuscularly for 10 days while in hospital, then 1 capsule twice a day for 2 months. In all patients before administration of the drug, after 10 days of in-hospital treatment and 2 months after treatment, clinical neurological examination was performed to evaluate neurological status, as well as dynamic examination using special clinical questionnaires (scales): Neurological Symptom Score and Total Symptom Score. Results. Patients in both the first group and the second groups had a statistically positive effect on the symptoms after 10 days of in-patient treatment according to Neurological Symptom Score. The severity of neuropathy in first group before treatment was 10.23 ± 0.35 points, and after treatment — 7.62 ± 0.26 points, p < 0.001; in the second group, before treatment — 10.23 ± 0.35 points, and after treatment — 8.00 ± 0.30 points, p < 0.001. According to Total Symptom Score, the severity of neuropathy symptoms decreased significantly in both group 1 (8.27 ± 0.47 points before treatment and 6.27 ± 0.12 points after treatment, p < 0.001) and group 2 (8.40 ± 0.45 points before treatment and 6.53 ± 0.14 points after treatment, p < 0.001). Further studies showed that after 2 months of treatment in patients in first group, Neurological Symptom Score (10.23 ± 0.35 points, p > 0.05) and Total Symptom Score (7.87 ± 0.38 points, p > 0.05) returned to the baseline or the changes were unreliable. Two-month administration of Nucleo C.M.P. Forte had a statistically positive effect on the symptoms of neuropathy according to Neurological Symptom Score (7.27 ± 0.51 points, p < 0.001) and Total Symptom Score (6.53 ± 0.14 points, p < 0.001). Conclusions. The use of Nucleo C.M.P. Forte in the comprehensive treatment of patients with diabetes mellitus can prevent disorders that occur as a result of diabetic polyneuropathy. Long-term statistically significant positive effect of Nucleo C.M.P. Forte on neuropathy symptoms was revealed.http://iej.zaslavsky.com.ua/article/view/180042diabetes mellitusdiabetic polyneuropathynucleo c.m.p. forte |
| spellingShingle | M.V. Vlasenko A.V. Palamarchuk S.V. Shkarivska The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy Mìžnarodnij Endokrinologìčnij Žurnal diabetes mellitus diabetic polyneuropathy nucleo c.m.p. forte |
| title | The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy |
| title_full | The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy |
| title_fullStr | The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy |
| title_full_unstemmed | The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy |
| title_short | The use of Nucleo C.M.P. Forte in the comprehensive treatment of diabetic polyneuropathy |
| title_sort | use of nucleo c m p forte in the comprehensive treatment of diabetic polyneuropathy |
| topic | diabetes mellitus diabetic polyneuropathy nucleo c.m.p. forte |
| url | http://iej.zaslavsky.com.ua/article/view/180042 |
| work_keys_str_mv | AT mvvlasenko theuseofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy AT avpalamarchuk theuseofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy AT svshkarivska theuseofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy AT mvvlasenko useofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy AT avpalamarchuk useofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy AT svshkarivska useofnucleocmpforteinthecomprehensivetreatmentofdiabeticpolyneuropathy |